Bryan Dirks
About
Bryan Dirks is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Pharmacology.
According to data from OpenAlex, Bryan Dirks has authored 37 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 18 papers in Cognitive Neuroscience and 6 papers in Pharmacology. Recurrent topics in Bryan Dirks's work include Attention Deficit Hyperactivity Disorder (21 papers), Bipolar Disorder and Treatment (8 papers) and Functional Brain Connectivity Studies (8 papers). Bryan Dirks is often cited by papers focused on Attention Deficit Hyperactivity Disorder (21 papers), Bipolar Disorder and Treatment (8 papers) and Functional Brain Connectivity Studies (8 papers). Bryan Dirks collaborates with scholars based in United States, Spain and Germany. Bryan Dirks's co-authors include Robert Lasser, Richard H. Weisler, Lenard A. Adler, Ben Adeyi, T. Babcock, D. Wayne Goodman, Aparna Raychaudhuri, Stephen V. Faraone, Joseph Gao and Carla M. Canuso and has published in prestigious journals such as American Journal of Psychiatry, Neuropsychopharmacology and Journal of Affective Disorders.
In The Last Decade
Bryan Dirks
37 papers receiving 580 citations
Peers
Bryan Dirks
Angelo Fallu Canada
Larry J. Klassen Canada
Maija Konstenius Sweden
Todd M. Durell United States
Christopher S. Sarampote United States
Aaron J. Bobb United States
Tatiana Usala Italy
Anna Ceraso Italy
Jilian M. Mulqueen United States
B. Jabs Germany
Citations per year, relative to Bryan Dirks Bryan Dirks (= 1×)
peers
Angelo Fallu
Countries citing papers authored by Bryan Dirks
Since
Specialization
Citations
This map shows the geographic impact of Bryan Dirks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Dirks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Dirks more than expected).
Fields of papers citing papers by Bryan Dirks
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bryan Dirks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Dirks. The network helps show where Bryan Dirks may publish in the future.
Co-authorship network of co-authors of Bryan Dirks
This figure shows the co-authorship network connecting the top 25 collaborators of Bryan Dirks. A scholar is included among the top collaborators of Bryan Dirks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan Dirks. Bryan Dirks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dirks, Bryan, et al.. (2025). Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies. Psychopharmacology Bulletin. 52(4). 8–30.
2.
Shelton, Richard C., Maurizio Fava, Marlene P. Freeman, et al.. (2020). Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. Journal of Affective Disorders. 277. 478–485.
3.
Papakostas, George I., Maurizio Fava, Marlene P. Freeman, et al.. (2020). Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. International Clinical Psychopharmacology. 35(6). 313–321.
4.
Jha, Manish K., Maurizio Fava, Marlene P. Freeman, et al.. (2020). Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 82(1).
5.
Fava, Maurizio, Bryan Dirks, Marlene P. Freeman, et al.. (2019). A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). The Journal of Clinical Psychiatry. 80(6).
6.
Huß, Michael, Bryan Dirks, Joan Gu, et al.. (2018). Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. European Child & Adolescent Psychiatry. 27(10). 1283–1294.
7.
Martin, Patrick, Bryan Dirks, Lev Gertsik, et al.. (2014). Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia. Journal of Clinical Psychopharmacology. 34(6). 682–689.
8.
Dirks, Bryan, et al.. (2013). Treatment Outcomes with Lisdexamfetamine Dimesylate in Children Who Have Attention-Deficit/Hyperactivity Disorder with Emotional Control Impairments. Journal of Child and Adolescent Psychopharmacology. 23(6). 386–393.
9.
Findling, Robert L., Ben Adeyi, Bryan Dirks, et al.. (2013). Parent-Reported Executive Function Behaviors and Clinician Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in Children Treated with Lisdexamfetamine Dimesylate. Journal of Child and Adolescent Psychopharmacology. 23(1). 28–35.
10.
Mattingly, Gregory W., Richard H. Weisler, Joel Young, et al.. (2013). Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 13(1). 39–39.
11.
Weisler, Richard H., et al.. (2013). Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate. Neuropsychiatric Disease and Treatment. 10. 1–1.
12.
Adler, Lenard A., et al.. (2013). Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study. BMC Psychiatry. 13(1). 253–253.
13.
Jain, Rakesh K., et al.. (2013). Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use. Advances in Therapy. 30(5). 472–486.
14.
Babcock, T., et al.. (2012). Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study. BMC Pharmacology and Toxicology. 13(1). 18–18.
15.
Jain, Rakesh K., et al.. (2011). Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child and Adolescent Psychiatry and Mental Health. 5(1). 35–35.
16.
Turgay, Atilla, Lawrence Ginsberg, Elias Sarkis, et al.. (2010). Executive Function Deficits in Children with Attention-Deficit/Hyperactivity Disorder and Improvement with Lisdexamfetamine Dimesylate in an Open-Label Study. Journal of Child and Adolescent Psychopharmacology. 20(6). 503–511.
17.
Findling, Robert L., Ben Adeyi, Gary Chen, et al.. (2010). Clinical Response and Symptomatic Remission in Children Treated With Lisdexamfetamine Dimesylate for Attention-Deficit/Hyperactivity Disorder. CNS Spectrums. 15(9). 559–568.
18.
Canuso, Carla M., Bryan Dirks, Jennifer Carothers, et al.. (2009). Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia. American Journal of Psychiatry. 166(6). 691–701.
19.
Dirks, Bryan. (1998). Repetition of parasuicide —ICD‐10 personality disorders and adversity. Acta Psychiatrica Scandinavica. 98(3). 208–213.
20.
Brink, Johann, et al.. (1992). South African psychiatrists' attitudes to the present implementation of the Abortion and Sterilisation Act of 1975.. PubMed. 82(6). 434–6.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Angelo Fallu Breakdown of academic impact, for papers by Larry J. Klassen Breakdown of academic impact, for papers by Maija Konstenius Breakdown of academic impact, for papers by Todd M. Durell Breakdown of academic impact, for papers by Christopher S. Sarampote Breakdown of academic impact, for papers by Aaron J. Bobb Breakdown of academic impact, for papers by Tatiana Usala Breakdown of academic impact, for papers by Anna Ceraso Breakdown of academic impact, for papers by Jilian M. Mulqueen Breakdown of academic impact, for papers by B. Jabs